CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Lanthanum Carbonate +1 moredrug
Likely dose
Lanthanum Carbonate 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00875017
NCT00875017Phase 1Completed
CompareCT.gov

An Open-label, Phase I, One-dose, One-meal, Balance Study Comparing the Absorption of Dietary Phosphorus When Administering FOSRENOL® (Lanthanum Carbonate) or RENVELA® (Sevelamer Carbonate) in Healthy Adult Volunteers

Shire·interventional·Posted Apr 3, 2009·Updated Jun 15, 2021

In Brief

A Phase 1 clinical trial evaluating Lanthanum Carbonate and Sevelamer for Kidney Failure, Chronic. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Failure, Chronic
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 3, 2009
Enrollment StartApr 20, 2009
Primary CompletionJun 16, 2009
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 17.2 years ago

Interventions

Lanthanum Carbonatedrug

1 x 1000mg tablet

Sevelamerdrug

3 x 800mg tablets